Saxenda vs Liraglutide Generic: How to Switch Between Them Safely

Print or save as PDFOpens the printable medication review sheet and your print dialog. No sign-up.

Two kinds of generic liraglutide

Saxenda and Victoza are separate Novo Nordisk products that both contain the GLP-1 receptor agonist liraglutide, given as a once-daily subcutaneous injection [2]. Saxenda (NDA 206321, approved 2014-12-23) is the weight-management product; Victoza (NDA 022341, approved 2010-01-25) is the type 2 diabetes product [2].

The FDA-approved generics do not all point back to the same brand. The generics that reference Saxenda carry the weight-management labeling, including labels from Teva (ANDA 214568), Biocon (ANDA 217063) and Cipla (ANDA 217234). The generics that reference Victoza carry the type 2 diabetes labeling, including Hikma (ANDA 215503, approved 2024-12-23), Lupin, Meitheal/NorthStar and a Teva authorized generic [1]. Which labeling a product carries follows from the brand it references.

Switching to a generic that references Saxenda

This is a change of manufacturer inside the same indication. Saxenda's label describes starting at 0.6 mg daily for one week and stepping up weekly to 1.2 mg, 1.8 mg, 2.4 mg, then 3 mg from week 5 onward, injected at any time of day without regard to meals [2]. The label's recommended adult dose is 3 mg daily, and lower doses are for titration only [2].

For a missed dose, the Saxenda label says to resume the once-daily regimen with the next scheduled dose and not to take an extra dose to make up for it [2].

The label also sets its own checkpoint: weight change is evaluated 16 weeks after starting, and treatment is discontinued if less than 4% of baseline body weight has been lost [2].

Switching to a diabetes-labeled generic

Here the prescription changes purpose as well as product. Victoza-referenced generics carry type 2 diabetes labeling, so their labeled use differs from Saxenda's weight-management indication [1]. Victoza's maximum labeled dose is 1.8 mg daily [1].

The only dose comparison here comes from one trial that randomized people to a dose, not from a study of switching products. SCALE Diabetes randomized 846 adults with type 2 diabetes and overweight or obesity to liraglutide 3.0 mg (423 people), 1.8 mg (211) or placebo (212), alongside a 500 kcal/day deficit and increased physical activity. Weight fell 6.0% at 3.0 mg, 4.7% at 1.8 mg and 2.0% on placebo, and at least 5% of body weight was lost by 54.3%, 40.4% and 21.4% respectively [3]. These are group averages, not individual outcomes.

For what happens when treatment stops, the adolescent trial reported that weight regain after stopping was greater with liraglutide than with placebo [4].

Combining liraglutide products

The Saxenda label does not recommend using Saxenda together with another liraglutide-containing product or any other GLP-1 receptor agonist [2].

Compounded liraglutide sits outside this comparison. Compounded drugs are not FDA approved [5]. On 2026-04-30 FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the list of bulk substances outsourcing facilities may compound with, finding no clinical need; comments ran to 2026-06-29 and no final decision was found [6].

The 3-day rule after a gap

If more than 3 days have elapsed since the last Saxenda dose, the Saxenda label says to reinitiate treatment at 0.6 mg daily and follow the dose escalation schedule again, to reduce the risk of gastrointestinal adverse reactions associated with reinitiation [2]. The label does not give a separate rule for changing products.

Side effects at the 3 mg dose

In the adult Saxenda trials (5 placebo-controlled trials, 3,384 people on Saxenda vs 1,941 on placebo, up to 56 weeks at 3 mg), nausea occurred in 39.3% vs 13.8%, diarrhea in 20.9% vs 9.9%, constipation in 19.4% vs 8.5% and vomiting in 15.7% vs 3.9%. Treatment was stopped for adverse reactions by 9.8% vs 4.3%, most often for nausea (2.9% vs 0.2%); nausea declined as treatment continued [2].

Heart rate is another labeled effect. Mean resting heart rate rose 2 to 3 bpm, and 34% vs 19% had changes from baseline of more than 10 bpm at two consecutive visits; the label says to monitor heart rate at regular intervals [2].

Hypoglycemia risk depends on what else is being taken. In adults with type 2 diabetes on a sulfonylurea, glucose under 54 mg/dL with or without symptoms occurred in 28.2% on Saxenda vs 12.7% on placebo, with the sulfonylurea dose cut 50% at the start of the trial; the label says the risk may be lowered by reducing the insulin or secretagogue dose [2].

Labeled safety warnings

Saxenda's label carries a boxed warning about thyroid C-cell tumors in rats and mice, with human relevance undetermined. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or MEN 2, or with a serious hypersensitivity to liraglutide or an excipient [2].

Warning symptoms named in the label

For acute pancreatitis, the label describes persistent or severe abdominal pain, sometimes radiating to the back and possibly with vomiting, and directs discontinuing the drug and starting appropriate management if pancreatitis is suspected [2]. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and the label directs stopping the drug and promptly seeking medical advice [2]. The label lists a mass in the neck, difficulty swallowing or breathing, and persistent hoarseness as symptoms of thyroid tumors [2].